Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
WHOPAR Guidance for Applicants
(2004; 140 pages)
Table of Contents
View the documentGuidance note to Applicants (Manufacturers) on the compilation of the WHO Public Assessment Report version 1.0 - December 2004
View the documentAppendix 1 - Characteristics of WHOPAR Parts
View the documentAppendix 2 - Documentation to submit together with the initial submission
Open this folder and view contentsAppendix 3 - Guidance on Package Leaflet, Summary of Product Characteristics and Labelling
View the documentAppendix 4 - Format of the Summary of Product Safety and Efficacy

Appendix 4 - Format of the Summary of Product Safety and Efficacy

The purpose of the Summary of Product Safety and Efficacy is to provide current information on the safety and efficacy of the product in support of the information provided in the Package Leaflet and Summary of Product Characteristics. The summary should be 4 - 6 pages long (or more as appropriate, in case of a multisource product where no innovator or comparator/reference product is available) and should be written in easily understandable English to be useful to all interested parties.

The summary should provide an integrated evaluation of the product and not just a summation of the product information for the individual actives contained in e.g. - fixed dose combinations. Similarly for such products the rationale for use of the product should be in terms of the combination. Further guidance is provided in the WHO "Guidelines for Registration of Fixed Dose Combination Medicinal Products"1 (September 2004).


The outline for the Summary of Product Safety and Efficacy should follow the format described below:

1. Introduction

a. Background
b. Product Design
c. Unique product characteristics
d. Approved indication(s)

2. Clinical pharmacology

a. Pharmacodynamics
b. Pharmacokinetics

i. Special populations

3. Drug Interactions; related side effects and contra indications

4. Clinical Efficacy

a. Controlled studies
b. Observational studies
c. Supportive studies
d. Clinical studies in special populations

i. Kidney dysfunction
ii. Liver dysfunction
iii. Pediatric

For each population information should be presented by patient categories as relevant to the FPP e.g. for FDC's antiretroviral naïve - and experienced patients.

5. Clinical Safety

a. Patient exposure
b. Serious adverse events/deaths
c. Adverse events

6. Benefit risk assessment

For documents referenced in the Summary, e.g. scientific articles, copies of the underlying documentation should be provided.

to previous section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019